Loss of PI(4,5)P2 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 470-481

  Ye, Yan ^a   Li, Qun ^a   Hu, Wang Lai ^b   Tseng, Hsin Yi ^c   Jin, Lei ^c   Zhang, Xu Dong ^c   Zhang, Lin Jie ^a   Yang, Sen ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 HYDROXYTESTOSTERONE; B RAF KINASE; BROXURIDINE; N [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 5 PHOSPHATASE; PLASMID VECTOR; PROTEIN BAD; PROTEIN KINASE B; PROTEIN MCL 1; SELUMETINIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84881036572     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13277     Document Type: Article

References (45)

1. Courtney KD, Corcoran RB, and Engelman JA (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28, 1075-1083.
2. Ferté C, André F, and Soria JC (2010). Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 7, 367-380.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
4. Smalley KS (2010). Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 130, 28-37.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507-2516.
6. Houslay MD (2011). Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell 19, 3-4.
7. Ribas A and Flaherty KT (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8, 426-433.
8. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, and Hirth P (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11, 873-886.
9. Nikolaou VA, Stratigos AJ, Flaherty KT, and Tsao H (2012). Melanoma: new insights and new therapies. J Invest Dermatol 132, 854-863.
10. Smalley KS and Sondak VK (2010). Melanoma-an unlikely poster child for personalized cancer therapy. N Engl J Med 363, 876-878.
11. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. (2010). Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
12. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
13. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
14. V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3, 724.
15. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106, 20411-20416.
16. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71, 2750-2760.
17. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
18. V600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17, 721-730.
19. Madonna G, Ullman CD, Gentilcore G, Palmieri G, and Ascierto PA (2012). NF-κB as potential target in the treatment of melanoma. J Transl Med 10, 53.
20. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367, 1694-1703.
21. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, et al. (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13, 782-789.
22. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, et al. (2012). Safety, pharmaco-kinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13, 773-781.
23. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, et al. (2012). The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18, 2316-2325.
24. Franke TF, Kaplan DR, and Cantley LC (1997). PI3K: downstream AKTion blocks apoptosis. Cell 88, 435-437.
25. Majerus PW, Kisseleva MV, and Norris FA (1999). The role of phosphatases in inositol signaling reactions. J Biol Chem 274, 10669-10672.
26. Park SJ, Itoh T, and Takenawa T (2001). Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli. J Biol Chem 276, 4781-4787.
27. Bozulic L and Hemmings BA (2009). PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21, 256-261.
28. Franke TF (2008). PI3K/Akt: getting it right matters. Oncogene 27, 6473-6488.
29. Gao T, Furnari F, and Newton AC (2005). PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18, 13-24.
30. Yamada T, Katagiri H, Asano T, Inukai K, Tsuru M, Kodama T, Kikuchi M, and Oka Y (2001). 3-Phosphoinositide-dependent protein kinase 1, an Akt1 kinase, is involved in dephosphorylation of Thr-308 of Akt1 in Chinese hamster ovary cells. J Biol Chem 276, 5339-5345.
31. Kisseleva MV, Cao L, and Majerus PW (2002). Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phos-phorylation and leads to apoptotic cell death. J Biol Chem 277, 6266-6272.
32. Ma K, Cheung SM, Marshall AJ, and Duronio V (2008). PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal 20, 684-694.
33. Ooms LM, Fedele CK, Astle MV, Ivetac I, Cheung V, Pearson RB, Layton MJ, Forrai A, Nandurkar HH, and Mitchell CA (2006). The inositol polyphosphate 5-phosphatase, PIPP, is a novel regulator of phosphoinositide 3-kinase-dependent neurite elongation. Mol Biol Cell 17, 607-622.
34. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, et al. (2010). Inositol polyphos-phate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA 107, 22231-22236.
35. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, et al. (2009). Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16, 115-125.
36. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, and Agoulnik IU (2011). Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 71,572-582.
37. Carracedo A, Alimonti A, and Pandolfi PP (2011). PTEN level in tumor suppression: how much is too little? Cancer Res 71, 629-633.
38. Ye Y, Jin L, Wilmott JS, Hu WL, Yosuf B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, et al. (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun 4, 1508.
39. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, et al. (2007). IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682-693.
40. Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, and Whitcombe D. (2008). Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54, 757-760.
41. V600E involves preferential splicing of bimS. Cell Death Dis 1, e69.
42. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, and Hersey P (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res 13, 4934-4942.
43. Patel SP and Kim KB (2012). Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21, 531-539.
44. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
45. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, Liu H, de Bock CE, Hersey P, and Zhang XD (2011). Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 30, 3716-3726.